TREATMENT OF SHIZOPHRENIC PATIENTS AND rTMS
Emmanuel Poulet, F. Haesebaert, M. Saoud, M.F. Suaud-Chagny & Jerome Brunelin
EA 4166, University Of Lyon, Lyon 1, Institut fédératif des neurosciences de Lyon,
CH le Vinatier 95 boulevard Pinel, 69 677 Bron Cedex, France

SUMMARY
Introduction: Schizophrenia (SCH) is a heterogeneous syndrome characterized by positive and negative symptoms. Despite appropriate medication, about 1/4 of patients suffer for refractory positive and/or negative symptoms which are associated with functional handicap, increase of duration and of the number of hospitalizations. Numerous studies have suggested that the pathophysiology of auditory hallucinations (AH) is related to a hyperactivity of the left temporoparietal cortex (TPC). On the other hand, negative symptoms are associated with a prefrontal hypoactivity and the efficiency of pharmacological treatments is frequently partial. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation tool with excellent tolerability and safety. Given its hypothesized mechanisms of action and the clinical beneficial effects obtained in several types of pathology (Aleman et al. 2007), the efficacy of rTMS has been investigated for drug-resistant SCH symptoms.

Objective: Our objective is to expose the knowledge concerning the rTMS use in the treatment of these symptoms and to propose a critical analysis of these data.

Method: a systematic review of the literature has been conducted using NIH Pubmed. The following search terms were used: TMS - rTMS - Schizophrenia - negative symptoms - hallucinations.

Results: Concerning the treatment of AH, 16 publications and 4 meta analyses were selected. For the negative symptoms, we retained 16 studies and 3 meta analyses. The most extensively investigated application for rTMS in SCH is the use of low-frequency stimulation to the left TPC with the aim to improve AH symptomatology. When compared to sham, this type of acute course of rTMS has been proven to induce a substantial and significant reduction in AH. But this effect does not seem long-lasting and maintenance protocols must be developed. Concerning negative symptoms, the results are less solid but we find some works which demonstrate an improvement of these symptoms while various stimulation parameters were used. Recently, new parameters of stimulation in particular the theta burst stimulation have permitted us to obtain larger effects with longer duration. The interest of these new parameters will be discussed here.

Conclusion: Overall, rTMS studies have demonstrated some promise in the treatment of SCH. However, more research is required to enhance rTMS efficacy and increase its beneficial effect duration and to test new therapeutic strategies in this topic.

Key words: rTMS - auditory hallucinations - negative symptoms - schizophrenia

Introduction

With a whole life prevalence of a little less than 1%, schizophrenia is a frequent and disabling pathology usually treated by pharmacological antipsychotic treatments. In spite of the efficiency of these treatments, some symptoms persist. Among positive symptoms, hallucinations (AH) and particularly hearing voices (AVH) are refractory to drug treatment in 25% of cases and negative symptoms are frequently only partly alleviated. Hence, the development of additional therapies constitutes a major step in caring for schizophrenic patients.

On a pathophysiological level, numerous studies have suggested that AH were associated with a hyperactivity of the left temporoparietal cortex (TPC) and negative symptoms with a hypoactivity of the prefrontal cortex. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation tool with an excellent tolerability and safety profile. rTMS delivered at a 1Hz frequency (slow or low-frequency rTMS) is assumed to decrease cortical excitability. In contrast, high-frequency rTMS (5-20 Hz) increases cortical excitability. During the 15 last years, given its hypothesized mechanism of action, efficacy of rTMS has been investigated for the treatment of both positive (e.g. hallucinations and delusions) and negative symptoms of schizophrenia.

Objective

Our objective is to expose the knowledge concerning rTMS use in the treatment of positive and negative symptoms of SCH and to propose a critical analysis of these data. This review summarizes the most relevant evidence in terms of efficacy and benefits effect duration according to the stimulation parameters and discusses about the progress in the particular field of new parameters of stimulation and future research in this area.

Methodology

A systematic review of the literature has been conducted using NIH Pubmed. The following search terms were used: TMS - rTMS - Schizophrenia - negative symptoms - hallucinations. The following data were analysed: number of patients - study design - parameters of treatment (frequency - technique for localisation - number of stimulations per session - rhythm of sessions). Our results are presented first in term of acute efficacy and secondly in term of maintenance protocols.
Table 1. High frequency rTMS effects on negative symptoms

<table>
<thead>
<tr>
<th>Study</th>
<th>n subjects (frequency)</th>
<th>Number of pulses</th>
<th>Rating scales</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Klein (1999) (14)</td>
<td>31 (1Hz)</td>
<td>1200</td>
<td>PANSS, HDRS</td>
<td>Negative</td>
</tr>
<tr>
<td>Rollnik (2000) (15)</td>
<td>12 (20Hz)</td>
<td>8000</td>
<td>BPRS</td>
<td>Positive</td>
</tr>
<tr>
<td>Hajak (2004) (16)</td>
<td>20 (10Hz)</td>
<td>1000</td>
<td>PANSS (PANSS Neg)</td>
<td>Positive</td>
</tr>
<tr>
<td>Jin (2006) (12)</td>
<td>37 (alpha TMS)</td>
<td>3 Hz = 1200, Alpha = 3600, 20 Hz= 8000</td>
<td>PANSS + PANSS Neg</td>
<td>Positive for alpha rTMS</td>
</tr>
<tr>
<td>Goyal (2007) (17)</td>
<td>10 (10 Hz)</td>
<td>9800</td>
<td>SANS, HDRS</td>
<td>Positive</td>
</tr>
<tr>
<td>Prikryl (2007) (18)</td>
<td>22 (10Hz)</td>
<td>2250</td>
<td>SANS</td>
<td>Positive</td>
</tr>
<tr>
<td>Holi (2004) (19)</td>
<td>22 (10Hz)</td>
<td>1000</td>
<td>PANSS</td>
<td>Negative</td>
</tr>
<tr>
<td>Novak (2006) (20)</td>
<td>16 (20Hz)</td>
<td>1200</td>
<td>PANSS</td>
<td>Negative</td>
</tr>
<tr>
<td>Mogg (2007)</td>
<td>17 (10Hz)</td>
<td>2000</td>
<td>PANSS</td>
<td>Negative</td>
</tr>
<tr>
<td>Schneider (2008)</td>
<td>51 (1 Hz vs 10 Hz vs Placebo)</td>
<td>20000</td>
<td>SANS</td>
<td>10 Hz &gt; 1 Hr = Placebo</td>
</tr>
<tr>
<td>Cortes (2010)</td>
<td>35 (10 Hz)</td>
<td>10000</td>
<td>PANSS-Neg, GCI</td>
<td>Positive</td>
</tr>
<tr>
<td>Cohen (1999)</td>
<td>6 (20Hz)</td>
<td>8000</td>
<td>BPRS</td>
<td>Positive</td>
</tr>
<tr>
<td>Nahas (1999) (21)</td>
<td>8 (20 Hz)</td>
<td>1600</td>
<td>SANS</td>
<td>Positive</td>
</tr>
<tr>
<td>Jandl (2005) (22)</td>
<td>10 (10 Hz)</td>
<td>3500</td>
<td>SANS</td>
<td>Positive</td>
</tr>
<tr>
<td>Sachdev 2005 (23)</td>
<td>4 (15 Hz)</td>
<td>36000</td>
<td>PANSS</td>
<td>Positive</td>
</tr>
</tbody>
</table>

PANSS = Positive and Negative Syndrome Scale; PANSS-Neg = Negative psychopathology subscale of the Positive and Negative Syndrome Scale; SANS = Scale for Assessment of Negative Symptoms; BPRS = Brief Psychiatric Rating Scale; HDRS = Hamilton Depression Rating Scale; MDD = Patients with Major Depressive Disorder; SCZ = Schizophrenic patients; CGI = Clinical Global Impression

Table 2. Low frequency rTMS effects on auditory hallucinations (AH)

<table>
<thead>
<tr>
<th>Study</th>
<th>n subjects (frequency)</th>
<th>Number of pulses</th>
<th>Rating scales</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fitzgerald (2005) (24)</td>
<td>33 (1Hz)</td>
<td>9000</td>
<td>PANSS, AHRS</td>
<td>Negative</td>
</tr>
<tr>
<td>Hoffman (2003) (25)</td>
<td>24 (1Hz)</td>
<td>2400</td>
<td>PANSS, AHRS</td>
<td>Positive</td>
</tr>
<tr>
<td>Hoffman (2005) (26)</td>
<td>51 (1Hz)</td>
<td>7290</td>
<td>PANSS, AHRS</td>
<td>Positive</td>
</tr>
<tr>
<td>Vercammen 2009 (27)</td>
<td>38 (1Hz)</td>
<td>14400</td>
<td>PANSS, AHRS</td>
<td>Positive, Left &gt; bilateral &gt; Sham</td>
</tr>
<tr>
<td>Poulet (2005) (3)</td>
<td>10 (1Hz)</td>
<td>10000</td>
<td>SAPS, AHRS</td>
<td>Positive</td>
</tr>
<tr>
<td>Brunelin (2006) (4)</td>
<td>24 (1Hz)</td>
<td>10000</td>
<td>AHRS</td>
<td>Positive</td>
</tr>
<tr>
<td>Schonfeldt-Lecuona (2004) (28)</td>
<td>12 (1Hz)</td>
<td>4800</td>
<td>AHRS</td>
<td>Negative</td>
</tr>
<tr>
<td>Rosa (2007) (29)</td>
<td>11 (1Hz)</td>
<td>9600</td>
<td>PANSS</td>
<td>Negative</td>
</tr>
<tr>
<td>Lee (2005) (30)</td>
<td>39 (1Hz)</td>
<td>12000</td>
<td>PANSS, AHRS</td>
<td>Positive, Right = Left &gt; Placebo</td>
</tr>
<tr>
<td>Chibbaro (2005) (31)</td>
<td>16 (1Hz)</td>
<td>3600</td>
<td>SAPS, AHRS</td>
<td>Positive</td>
</tr>
</tbody>
</table>

AHRS = Auditory Hallucinations Rating Scale; PANSS = Positive and Negative Syndrome Scale

Results

Concerning the treatment of AH, 16 publications and 4 meta analyses (see table 1) were selected. For the negative symptoms, we retained 16 studies and 3 meta analyses (see table 2).

In the treatment of persistent auditory hallucinations, the use of low-frequency rTMS targeting the TPC was first suggested and tested by Hoffman and colleagues (Hoffman et al. 1999). They developed extensive studies and have reported positive results in at least 5
Hallucinations Rating Scale (AHRS) which is a specific scale adapted from Hoffman et al. while PANSS or SAPS do not reveal a significant effect. However, the effect described with the low frequency rTMS does not seem long-lasting (8.5 weeks on average) and maintenance protocols have been developed. We described the case of a patient for whom a protocol of treatment of two monthly sessions during the same day allowed the disappearance of AH during one year (Poulet et al. 2007). Others suggested taking back a new treatment course (10 sessions) during relapses with very interesting results (Fitzgerald et al. 2006). Others proposed a progressive spacing of the sessions with a weekly session during six weeks, followed by one session every two weeks during three months, and then a session monthly during three months (Thirthalli et al. 2008). These modalities allowed maintaining efficiency during eight months following the cure. Further studies would be needed to improve maintenance strategies.

Recently, new parameters of stimulation have been proposed. On the one hand, Dollfus et al. have published positive results from a study including 11 patients treated in an open protocol using high frequency rTMS (20Hz) (Dollfus et al. 2008). On the other hand, other teams have obtained a positive effect on AH using continuous theta burst stimulation (cTBS) (Poulet et al. 2009, Sidhoumi). Those parameters could constitute an important advance: first, in terms of the treatment duration (2 days with high 20 Hz rTMS and less than 2 minutes per session with cTBS) and second, maybe in terms of duration of the effect.

Concerning negative symptoms, the results are less robust but we found some works which demonstrate an improvement of these symptoms while using various stimulation parameters. The high-frequency stimulation of the dorsolateral prefrontal cortex (DFPLC) seems today consensual and the lateralization to the left, more adapted to the functional neuroimaging data. The frequency of stimulation exhibiting the best clinical efficacy is 10 Hz according to the meta-analyze of Freitas et al. (Freitas et al. 2009). Because alpha rhythm power is inversely correlated with the severity of the negative symptomatology, Jin et al. recommend to use a frequency adjusted to the alpha rhythm of each subject (between 8 Hz and 12 Hz) (Jin 2006). This alpha-rTMS would have a superior efficacy to the treatment using 3 Hz and 20 Hz rTMS. To increase stimulation treatment efficacy on negative symptoms we also proposed to use intermittent theta burst stimulation (iTBS) giving remarkable benefits during 6 months as published in a case report (Bor 2009).

**Conclusion**

The most clearly advanced application of rTMS in SCH is the treatment of refractory AH. The data supporting the use of rTMS in the treatment of negative symptoms are currently less convincing. In any case, the data we presented here open important perspectives for the use of rTMS as an additional treatment of refractory symptoms.

**References**

magnetic stimulation in schizophrenia: a combined
treatment and neuroimaging study. Psychol Med 2004;
34:1157-63.
12. Hoffman RE, Boutrous NN, Berman RM, Roessler E, Belger
A, Krystal JH, et al. Transcranial magnetic stimulation of left
temporoparietal cortex in three patients reporting
13. Hoffman RE, Hawkins KA, Gueorguieva R, Boutrous NN,
Rachid F, Carroll K, et al. Transcranial magnetic
stimulation of left temporoparietal cortex and medication-
resistant auditory hallucinations. Arch Gen Psychiatry
2003; 60:49-56.
Boutrous NN, Wu YT, et al. Temporoparietal transcranial
magnetic stimulation for auditory hallucinations: safety,
efficacy and moderators in a fifty patient sample. Biol Psychiatry 2005;
58:97-104.
15. Holument JM, Eronen M, Toivonen K, Toivonen P, Marttunen
M, Naukkarininen L. Left prefrontal repetitive transcranial
magnetic stimulation in schizophrenia. Schizophr
Bull 2004;30:429-34.
D, et al. Changes in negative symptoms and EEG in
schizophrenic patients after repetitive transcranial
magnetic stimulation (rTMS): an open-label pilot study. J
et al. Therapeutic effects of individualized alpha frequency
transcranial magnetic stimulation (alphaTMS) on the
negative symptoms of schizophrenia. Schizophr Bull 2006;
32:556-61.
18. Klein E, Kolsky Y, Payerovsky M, Koren D, Chistyakov A,
Feinsod M. Right prefrontal slow repetitive transcranial
magnetic stimulation in schizophrenia: a double-blind
sham-controlled pilot study. Biol Psychiatry 1999;
46:1451-4.
19. Lee SH, Kim W, Chung YC, Jung KH, Bahk WM, Jun TY,
et al. A double blind study showing that two weeks of daily
repetitive TMS over the left or right temporoparietal
cortex reduces symptoms in patients with schizophrenia
who are having treatment-refractory auditory hallucina-
20. Nahas Z, McConnell K, Molloy M, Oliver N, Risch S,
Christie S, et al. Could left prefrontal rTMS modify
negative symptoms and attention in schizophrenia? Biol Psychiatry 1999;
45(8 Suppl 1):37S.
Klirova M, et al. The double-blind sham-controlled study of
high-frequency rTMS (20 Hz) for negative symptoms in
schizophrenia: negative results. Neuro Endocrinol Lett
22. Poulet E, Brunelin J, Bediou B, Bation R, Forgeard L,
Daley J, et al. Slow transcranial magnetic stimulation can
rapidly reduce resistant auditory hallucinations in
23. Poulet E, Brunelin J, Kallet L, d’Amato T, Saoud M.
Maintenance treatment of Auditory Hallucinations in
24. Poulet E, Brunelin J, Ben Makhlouf W, D’Amato T, Saoud
M. A case report of cTBS for the treatment of auditory
hallucinations in a patient with schizophrenia. Brain
25. Prikryl R, Kasparek T, Skotakova S, Ustohal L, Kucerova
H, Ceskova E. Treatment of negative symptoms of schizo-
phrenia using repetitive transcranial magnetic stimulation in
a double-blind, randomized controlled study. Schizophr
26. Rollnik JD, Haber TJ, Mogh H, Sigdel K, Kropp S,
Dengler R, et al. High frequency repetitive transcranial
magnetic stimulation (rTMS) of the dorsolateral prefrontal
cortex in schizophrenic patients. Neuroreport 2000;
11:4013-5.
27. Rosa MO, Gattaz WF, Rosa MA, Rumi DO, Tavares H,
Myczkowski M, et al. Effects of repetitive transcranial
magnetic stimulation on auditory hallucinations refractory
29. Schonfeldt-Lecuona C, Gron G, Walter H, Buchler N,
Wunderlich A, Spitzer M, et al. Stereotaxic rTMS for the
treatment of auditory hallucinations in schizophrenia.
30. Sidhoumi D, Braha S, Bouaziz N, Brunelin J, Benadjira R,
Januel D. Evaluation of the therapeutic effect of theta
burst stimulation on drug-resistant auditory hallucinations in
a schizophrenic patient and its impact on cognitive
function and neuronal excitability: a case study. Clin
Neurophysiol;121:802.
31. Thirthalli J, Bharadwaj B, Kulkarni S, Gangadhar BN,
Kharawala S, Andrade C. Successful use of maintenance
cTMS for 8 months in a patient with antipsychotic-
refractory auditory hallucinations. Schizophr Res 2007;
100:351-2.
32. Verscammen A, Kneitering H, Bruggeman R, Westenbroek
HM, Jenner JA, Slooff CJ, et al. Effects of bilateral
repetitive transcranial magnetic stimulation on treatment
resistant auditory-verbal hallucinations in schizophrenia: a
randomized controlled trial. Schizophr Res 2009;